Dosage of Losarhyd LD KO in details
Losarhyd LD KO Dosage
Generic name: Losartan (Losarhyd LD KO) potassium 50mg, Hydrochlorothiazide (Losarhyd LD KO) 12.5mg
Dosage form: tablet, film coated
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Hypertension
The usual starting dose of Losarhyd LD KO is 50/12.5 (Losartan (Losarhyd LD KO) 50 mg/Hydrochlorothiazide (Losarhyd LD KO) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losarhyd LD KO) 100 mg/Hydrochlorothiazide (Losarhyd LD KO) 25 mg) once daily as needed to control blood pressure.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losarhyd LD KO) 50 mg monotherapy with Losarhyd LD KO 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losarhyd LD KO 50/12.5 once daily or one tablet of Losarhyd LD KO 100/25 once daily.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losarhyd LD KO) 100 mg monotherapy with Losarhyd LD KO 100/12.5 (Losartan (Losarhyd LD KO) 100 mg/Hydrochlorothiazide (Losarhyd LD KO) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losarhyd LD KO 50/12.5 once daily or one tablet of Losarhyd LD KO 100/25 once daily.
Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losarhyd LD KO) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losarhyd LD KO 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losarhyd LD KO) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losarhyd LD KO 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losarhyd LD KO 50/12.5 once daily or one tablet of Losarhyd LD KO 100/25 once daily.
Hypertensive Patients with Left Ventricular Hypertrophy
In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losarhyd LD KO) potassium, initiate treatment with Losarhyd LD KO 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losarhyd LD KO 100/12.5, followed by Losarhyd LD KO 100/25. For further blood pressure reduction add other antihypertensives.
More about Losarhyd LD KO (Hydrochlorothiazide (Losarhyd LD KO) / Losartan (Losarhyd LD KO))
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 15 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Losarhyd LD KO
- Losarhyd LD KO (Advanced Reading)
Professional resources
- Losarhyd LD KO (FDA)
Related treatment guides
- High Blood Pressure
What other drugs will affect Losarhyd LD KO?
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Losarhyd LD KO, especially:
-
any other blood pressure medications;
-
steroids (prednisone and others);
-
lithium;
-
cholestyramine or colestipol;
-
insulin or oral diabetes medicine;
-
rifampin;
-
a barbiturate--phenobarbital and others;
-
any other diuretic or "water pill";
-
NSAIDs (non-steroidal anti-inflammatory drugs)--ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others;
-
a muscle relaxer--baclofen, carisoprodol, cyclobenzaprine, methocarbamol, tizanidine, and others; or
-
narcotic medicine--codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and others.
This list is not complete. Other drugs may interact with Losarhyd LD KO, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Losarhyd LD KO interactions
Agents Increasing Serum Potassium
Coadministration of Losartan (Losarhyd LD KO) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Lithium
Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losarhyd LD KO and lithium.
Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors
Losartan (Losarhyd LD KO) Potassium
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losarhyd LD KO)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losarhyd LD KO) and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losarhyd LD KO), may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Hydrochlorothiazide (Losarhyd LD KO)
The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losarhyd LD KO and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losarhyd LD KO), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losarhyd LD KO), Losartan (Losarhyd LD KO), and NSAID therapy.
Dual Blockade Of The Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losarhyd LD KO) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losarhyd LD KO) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
Closely monitor blood pressure, renal function, and electrolytes in patients on Losarhyd LD KO and other agents that affect the RAS.
Do not coadminister aliskiren with Losarhyd LD KO in patients with diabetes. Avoid use of aliskiren with Losarhyd LD KO in patients with renal impairment (GFR < 60 mL/min).
The Use Of Hydrochlorothiazide (Losarhyd LD KO) With Other Drugs
When administered concurrently, the following drugs may interact with thiazide diuretics :
Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.
Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losarhyd LD KO) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losarhyd LD KO) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losarhyd LD KO) and the resin such that Hydrochlorothiazide (Losarhyd LD KO) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.
References
- DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "JMS50MPO89: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Losarhyd LD KO are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losarhyd LD KO. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology